Latest
Amgen inks $180M nanomedicine deal
Thousand Oaks-based Amgen has entered a deal to pay up to $180.5 million for nanomedicine tumor treatments being developed by a Massachusetts company. Cambridge-based Bind Biosciences said it has entered a development agreement with Amgen for its kinase inhibitor nanomedicines for treating a range of solid tumors. The medicines are highly targeted and can be Read More →
Latest
Study targets diabetes
New research conducted on the South Coast could point the way to the prevention and cure of type two diabetes.
